January 18, 2024 8:57pm

MESO closed 1/18 down -$0.02 with a positive +$0.36 or +20.93% aftermarket indication

Rare Pediatric Disease (RPD) Designation followed submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life-threatening congenital heart condition.

RPD Designation is granted by the FDA for certain serious or life-threatening diseases which primarily affect children.

FDA approved its Biologics Licensing Application (BLA) for REVASCOR for the treatment of HLHS.

MESO may be eligible to receive a Priority Review Voucher (PRV) that can be redeemed for any subsequent marketing application or may be sold or transferred to a third party - might solve some of its cash from ATM usuage and "runway" issues


The Bottom Line: What a ride … enjoy the short-term

Finally, a positive for MESO which has suffered “bottoms” since approximately 1/10/24 in which it experienced a 1 for 2 stock-split dropping the equity to $1.88 which kept at it (dropping) until 1/18/24’s $1.72 having ended 2023 at $2.20.

MESO has tanked -89% over a three-year period.

2023 saw its share price down 68%.

it's also down -21% in about a quarter.

MESO shareholders are down -66% for 2023, but the market itself is up 10%.

Facing a total loss of 12% per year over five years

Over the last three years, Mesoblast's revenue dropped 41% per year. That means its revenue trend is very weak compared to other loss-making companies.

The swift share price decline at an annual compound rate of 24%, reflects this weak fundamental performance.

There is a good reason that investors often describe buying a sharply falling stock price as 'trying to catch a falling knife'. Think about it. <some numbers -- from Simply Wall Street>